PL2521562T3 - Ev576 do zastosowania w leczeniu zakażeń wirusowych dróg oddechowych - Google Patents

Ev576 do zastosowania w leczeniu zakażeń wirusowych dróg oddechowych

Info

Publication number
PL2521562T3
PL2521562T3 PL11700973T PL11700973T PL2521562T3 PL 2521562 T3 PL2521562 T3 PL 2521562T3 PL 11700973 T PL11700973 T PL 11700973T PL 11700973 T PL11700973 T PL 11700973T PL 2521562 T3 PL2521562 T3 PL 2521562T3
Authority
PL
Poland
Prior art keywords
treatment
respiratory tract
viral infections
infections
viral
Prior art date
Application number
PL11700973T
Other languages
English (en)
Polish (pl)
Inventor
Wynne Weston-Davies
Original Assignee
Volution Immuno Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1000318.4A external-priority patent/GB201000318D0/en
Priority claimed from GBGB1005071.4A external-priority patent/GB201005071D0/en
Application filed by Volution Immuno Pharmaceuticals Sa filed Critical Volution Immuno Pharmaceuticals Sa
Publication of PL2521562T3 publication Critical patent/PL2521562T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL11700973T 2010-01-08 2011-01-10 Ev576 do zastosowania w leczeniu zakażeń wirusowych dróg oddechowych PL2521562T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1000318.4A GB201000318D0 (en) 2010-01-08 2010-01-08 Method of treatment
GBGB1005071.4A GB201005071D0 (en) 2010-03-25 2010-03-25 Method of treatment
EP11700973.8A EP2521562B1 (en) 2010-01-08 2011-01-10 Ev576 for use in the treatment of viral infections of the respiratory tract
PCT/GB2011/000022 WO2011083317A1 (en) 2010-01-08 2011-01-10 Ev576 for use in the treatment of viral infections of the respiratory tract

Publications (1)

Publication Number Publication Date
PL2521562T3 true PL2521562T3 (pl) 2020-04-30

Family

ID=44305222

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11700973T PL2521562T3 (pl) 2010-01-08 2011-01-10 Ev576 do zastosowania w leczeniu zakażeń wirusowych dróg oddechowych

Country Status (9)

Country Link
US (4) US20120283167A1 (https=)
EP (1) EP2521562B1 (https=)
JP (1) JP5840623B2 (https=)
CN (1) CN102762223B (https=)
AU (2) AU2011204483B2 (https=)
CA (1) CA2785612C (https=)
NZ (1) NZ601018A (https=)
PL (1) PL2521562T3 (https=)
WO (1) WO2011083317A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2940319A1 (en) * 2014-03-20 2015-09-24 Inflarx Gmbh Inhibitors of c5a for the treatment of viral pneumonia
GB201410116D0 (en) * 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
GB201602802D0 (en) 2016-02-17 2016-03-30 Volution Immuno Pharmaceuticals Sa Method of treatment
CN116769024A (zh) 2016-06-14 2023-09-19 瑞泽恩制药公司 抗c5抗体及其用途
US11730792B2 (en) 2017-04-21 2023-08-22 Volution Immuno Pharmaceuticals Sa Coversin (OmCI) for the treatment of autoimmune blistering diseases: bullous pemphigoid (BP) and epidermolysis bullosa acquisita (EBA)
CA3274059A1 (en) 2017-12-13 2026-03-02 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof
EP3758737A4 (en) 2018-03-02 2022-10-12 Kodiak Sciences Inc. IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
JP7629394B2 (ja) 2018-09-10 2025-02-13 ヴォリューション イミュノ ファーマシューティカルズ エスエイ リウマチ性疾患の治療に使用するためのコバーシン
GB201905810D0 (en) 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
US11607428B2 (en) 2019-06-06 2023-03-21 Spiritus Therapeutics, Inc. Mesenchymal stem cell-derived extracellular vesicles and uses thereof for treating and diagnosing fibrotic diseases
US12097222B2 (en) 2019-06-06 2024-09-24 Spiritus Therapeutics, Inc. Methods for attenuating viral infection and for treating lung injury
WO2020247675A1 (en) * 2019-06-06 2020-12-10 Spiritus Therapeutics, Inc. Methods for attenuating viral infection and for treating lung injury
US20220370556A1 (en) 2019-09-27 2022-11-24 Volution Immuno Pharmaceuticals Sa Method of Treatment
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN120346194A (zh) * 2020-04-01 2025-07-22 硫创治疗公司 用于治疗乙型冠状病毒感染的半胱胺前体化合物
WO2021226404A1 (en) * 2020-05-08 2021-11-11 Kodiak Sciences Inc. Use of il-6 antibodies and vegf traps, and fusion constructs and conjugates thereof
GB202218084D0 (en) 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins
GB202408081D0 (en) 2024-06-06 2024-07-24 Volution Immuno Pharmaceuticals Sa Methods of removing impurities

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993017099A1 (en) 1992-02-27 1993-09-02 Merck & Co., Inc. Protein for inhibiting collagen-stimulated platelet aggregation
US7884066B2 (en) 1999-10-05 2011-02-08 The Regents Of The University Of California NELL-1 enhanced bone mineralization
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
EP1629098B1 (en) 2003-06-02 2009-04-01 Varleigh Limited Complement inhibitors from ticks
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
WO2007117241A1 (en) * 2006-04-12 2007-10-18 Biocryst Pharmaceuticals, Inc. Intramuscular antiviral treatments
US7274999B1 (en) * 2006-03-10 2007-09-25 Atmel Corporation Brownout detector system and method
PL2061501T3 (pl) * 2006-09-08 2016-01-29 Volution Immuno Pharmaceuticals Sa Sposób leczenia zaburzeń oddechowych
GB0617734D0 (en) * 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
GB0802116D0 (en) * 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment

Also Published As

Publication number Publication date
JP5840623B2 (ja) 2016-01-06
CA2785612A1 (en) 2011-07-14
CA2785612C (en) 2019-09-10
JP2013516450A (ja) 2013-05-13
NZ601018A (en) 2013-09-27
US9522171B2 (en) 2016-12-20
EP2521562B1 (en) 2019-09-18
AU2016203058B2 (en) 2018-01-18
AU2011204483A1 (en) 2012-07-12
AU2011204483B2 (en) 2016-02-11
AU2016203058A1 (en) 2016-06-02
US20150196619A1 (en) 2015-07-16
EP2521562A1 (en) 2012-11-14
US20170065677A1 (en) 2017-03-09
WO2011083317A1 (en) 2011-07-14
US20120283167A1 (en) 2012-11-08
CN102762223B (zh) 2014-09-03
US20200155646A1 (en) 2020-05-21
CN102762223A (zh) 2012-10-31

Similar Documents

Publication Publication Date Title
PL2521562T3 (pl) Ev576 do zastosowania w leczeniu zakażeń wirusowych dróg oddechowych
HUS2400017I1 (hu) Dolutegravir és lamivudin kombinációi HIV-fertõzés kezelésére
SI2627334T1 (sl) Sestavki za uporabo pri zdravljenju virusnih infekcij
ZA201500921B (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diaseases
IL232046A (en) Furein derivatives for the treatment of viral infections
ZA201308746B (en) Quinazoline derivatives for the treatment of viral infections and further diseases
ZA201502238B (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
IL222333A0 (en) Use of streptococcus salivarius in the treatment of chronic infections of the respiratory tract
GB201002243D0 (en) Respiratory disease treatment
PL2903608T3 (pl) Kompozycja farmaceutyczna obejmująca kwas propionowy do stosowania w leczeniu infekcji wirusowych
GB201002224D0 (en) Respiratory disease treatment
GB2515440B (en) Vesicular Formulations for use in the treatment of Rosacea
PL2544705T3 (pl) Interferon beta do zastosowania w leczeniu schorzenia dolnych dróg oddechowych powodowanego przez grypę
ZA201306342B (en) The treatment of viral infections
GB201012168D0 (en) Treatment of viral infections
GB201001821D0 (en) Treatment of viral infections
GB201001903D0 (en) Respiratory disease treatment
GB2477540A8 (en) Respiratory disease treatment
SI2315580T1 (sl) Farmacevtski pripravki in postopki za zdravljenjeinfekcij respiratornega trakta
GB0913914D0 (en) Treatment of viral infections
GB0919711D0 (en) Treatment of viral infections